Results · Apr-Jun 2026
Ishita Drugs & Industries Q1 FY27 results
Sales fell 42% to ₹3.1 crore from ₹5.4 crore in Apr-Jun 2025.
Operating profit fell 8% to ₹0.32 crore, an operating margin of 10.1% (up 3.7 points from a year ago).
Net profit fell 24% to ₹0.23 crore from ₹0.3 crore in Apr-Jun 2025.
Against Jan-Mar 2026: sales +3%, net profit +30%.
Apr-Jun 2026 vs a year ago
| ₹ crore | Apr-Jun 2026 | Apr-Jun 2025 | Change |
|---|---|---|---|
| Sales | 3.1 | 5.4 | −42% |
| Operating profit (EBITDA) | 0.3 | 0.3 | −8% |
| Operating margin | 10.1% | 6.4% | +3.7 pts |
| Net profit | 0.2 | 0.3 | −24% |
Standalone figures. Margins & ratios change in percentage points (pts).
The last 7 quarters
From the company's results filed on BSE (Standalone). Business numbers only. Education & analysis, not investment advice or a recommendation.